Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Ipilimumab + Radiotherapy|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Ipilimumab||Yervoy||BMS-734016||CTLA4 Antibody 18 Immune Checkpoint Inhibitor 98||Yervoy (ipilimumab) is an antibody that binds to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), causing increased T-cell activation (PMID: 28891423). Yervoy (ipilimumab) is FDA approved for use in patients with metastatic melanoma, including patients 12 years or older, and in combination with Opdivo (nivolumab) for intermediate or poor-risk renal cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (including patients 12 years or older), hepatocellular carcinoma previously treated with Nexavar (sorafenib), in combination with Opdivo (nivolumab) as first-line therapy in patients with PD-L1-positive (>=1%) metastatic non-small cell lung cancer without EGFR or ALK alterations, and in combination with Opdivo (nivolumab) and platinum-based chemotherapy as first-line therapy in patients with metastatic or recurrent non-small cell lung cancer without EGFR or ALK alterations (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||melanoma||not applicable||Ipilimumab + Radiotherapy||Clinical Study||Actionable||In a retrospective study, Yervoy (ipilimumab) in combination with local tumor treatment consisting of radiotherapy or electrochemotherapy resulted in improved median overall survival (93 weeks) compared to Yervoy (ipilimumab) alone (42 weeks) in advanced melanoma patients (PMID: 27466265).||27466265|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|